Pneumonia Viva

Long Case Viva Defence

Candidate's opening statement (model answer)

'Mrs Patel is a 72-year-old retired teacher and 40 pack-year smoker who presents with a 3-day history of fever, rigors, rusty sputum, and progressive dyspnoea, culminating in confusion at home. She has COPD (FEV1 55% predicted) and type 2 diabetes. [1]

On arrival she was confused, tachypnoeic at 34, hypotensive at 82/54, febrile at 39.2, and hypoxic with SpO2 86% on room air. Her CXR shows right middle and lower lobe consolidation with a 25 mm right pleural effusion. Blood urea 11.5, sodium 130, CRP 280, lactate 3.2. [1]

Her CURB-65 is 5, her PSI is class V, and she meets IDSA/ATS major criteria for severe CAP. Her blood cultures grew Streptococcus pneumoniae. Her SMART-COP score is 7. [1]

Her main problems are:

1. Severe bacteraemic pneumococcal CAP with septic shock — immediate threat to life
2. A right parapneumonic effusion requiring diagnostic thoracentesis
3. COPD and type 2 diabetes — modifying her management and prognosis
4. Ongoing smoking — a key modifiable risk factor
5. Functional decline and rehabilitation needs' [1]

Examiner probing questions and model answers

Q1: 'Walk me through your immediate management of this patient in the first hour.' [1]

'My priorities follow the Sepsis Six and the principles of time-critical sepsis management. First, I give high-flow oxygen targeting SpO2 94-98% — she does not have documented CO2 retention, but given her COPD I would check an arterial blood gas at 30-60 minutes and narrow the target to 88-92% if she is retaining CO2. Second, I take two sets of blood cultures and send a lactate — the lactate is already 3.2, confirming tissue hypoperfusion. Third, and most time-critical, I administer broad-spectrum antibiotics within the first hour — piperacillin-tazobactam 4.5 g IV plus azithromycin 500 mg IV — because the single most important intervention in septic shock is early appropriate antibiotics. Fourth, I give 30 mL/kg of balanced crystalloid IV over the first 3 hours and reassess her fluid responsiveness. Fifth, I insert a urinary catheter for hourly monitoring and start noradrenaline via a central line if she remains hypotensive after fluid resuscitation, titrating to a mean arterial pressure of at least 65. Sixth, I send pneumococcal and Legionella urinary antigens and a sputum culture. I would admit her to the ICU given her septic shock and the need for vasopressors.' [1]

Q2: 'Why piperacillin-tazobactam rather than ceftriaxone?' [1]

'Both are acceptable. Ceftriaxone 2 g IV daily is the more standard choice for severe CAP without Pseudomonas risk factors, and it would certainly cover pneumococcus. I chose piperacillin-tazobactam because she has COPD with significant lung disease, putting her at higher risk of Haemophilus influenzae and, over time, potential Pseudomonas colonisation. Pip-tazo provides anti-pseudomonal cover as a prudent precaution in a very sick patient with structural lung disease. If her cultures grow only penicillin-sensitive pneumococcus, I would de-escalate to ceftriaxone or even benzylpenicillin. The key principle is that the empiric regimen in severe CAP must be broad enough to cover the likely organisms including atypicals — which is why I also have the azithromycin — and then de-escalate once the organism and sensitivities are known.' [1]

Q3: 'Her blood cultures are positive for Streptococcus pneumoniae. Does this change your management?' [1]

'Yes, in three ways. First, I confirm the organism and its antibiotic sensitivities — penicillin-sensitive pneumococcus allows de-escalation to ceftriaxone or benzylpenicillin. Second, bacteraemic pneumococcal pneumonia carries a higher mortality (approximately 15-25%) than non-bacteraemic CAP, and I must actively look for metastatic infection — I examine for meningismus and consider a lumbar puncture if she has meningitic signs or persistent confusion out of proportion to her sepsis, I listen for a new murmur suggesting endocarditis and arrange an echocardiogram if bacteraemia is persistent, and I examine the joints and abdomen for septic arthritis and peritonitis. Third, I extend the duration of therapy — bacteraemic pneumococcal CAP typically requires 7-14 days, longer than the 5-day minimum for uncomplicated CAP, especially if there is metastatic seeding. The Austrian triad — pneumonia, meningitis, and endocarditis from pneumococcus — is rare but lethal and must be considered.' [1]

Q4: 'Would you give her corticosteroids?' [1]

'Yes. She has severe CAP — CURB-65 of 5, septic shock, and she meets the IDSA/ATS major criteria for severe CAP. The evidence supports adjunctive corticosteroids in this group. The Blum et al. trial in the Lancet in 2015 showed that prednisone 50 mg orally daily for 7 days shortened time to clinical stability by approximately 1.5 days in hospitalised CAP, and the Siemieniuk meta-analysis in Annals of Internal Medicine the same year showed that corticosteroids reduced mortality with a relative risk of 0.67, reduced mechanical ventilation with a relative risk of 0.45, and reduced ARDS with a relative risk of 0.24, with the benefit concentrated in severe CAP. The main adverse effect was hyperglycaemia requiring treatment — a relative risk of 1.49 — which I would manage with careful blood glucose monitoring and an insulin sliding scale, because she has diabetes. I would give prednisone 50 mg daily for 7 days, or hydrocortisone 200 mg per day intravenously if she cannot tolerate oral.' [1]

Q5: 'How would you manage her right pleural effusion?' [1]

'She has a 25 mm effusion on lateral decubitus film alongside severe pneumonia, so it requires diagnostic thoracentesis. I would first perform a pleural ultrasound to characterise the effusion — its size, whether it is free-flowing or loculated, and whether there is echogenic material suggesting pus — and to mark a safe aspiration site. I would then aspirate 20-50 mL of pleural fluid and send it for pH using a blood gas analyser, protein, LDH, glucose, cell count and differential, Gram stain, and culture. I would classify the effusion using Light's criteria for exudate versus transudate, and use the pH and glucose to decide whether to drain. If the pH is over 7.20 and the fluid is clear, it is an uncomplicated parapneumonic effusion and antibiotics alone suffice. If the pH is between 7.0 and 7.20, or the fluid is loculated or culture-positive, it is a complicated parapneumonic effusion and I would insert a chest drain and consider intrapleural fibrinolytics such as tPA and DNase. If the pH is under 7.0 or the fluid is frankly purulent, it is an empyema and I would arrange definitive drainage, either with a chest drain plus fibrinolytics or surgical drainage by VATS. The key principle is that any parapneumonic effusion in a patient who is not improving must be sampled and drained if infected.' [1]

Q6: 'What is the role of the SMART-COP score, and why might you prefer it to CURB-65?' [1]

'SMART-COP was developed by Charles and colleagues in an Australian cohort specifically to predict the need for intensive respiratory or vasopressor support — the question that CURB-65 answers poorly. CURB-65 predicts 30-day mortality and is excellent for the admission decision, but it does not reliably predict who will need ICU. SMART-COP weights the physiological features that actually drive the need for organ support: low systolic blood pressure and low oxygen and low pH each score 2 points, while multilobar CXR involvement, low albumin, tachycardia, tachypnoea, and confusion each score 1. A SMART-COP score of 3 or more identifies approximately 92% of patients who will need intensive respiratory or vasopressor support, with a much better sensitivity than CURB-65 for ICU admission. In ANZ practice, SMART-COP is widely used alongside CURB-65 to make the ICU triage decision. For Mrs Patel, her SMART-COP is 7 — high risk — confirming the need for ICU-level care.' [1]

Q7: 'She recovers and is ready for discharge. What is your discharge and follow-up plan?' [1]

'My discharge plan addresses her acute illness, her comorbidities, and prevention. First, I confirm she is clinically stable — afebrile for 48-72 hours, tolerating oral intake, normalising inflammatory markers, and off supplemental oxygen or on her baseline oxygen if she was on LTOT for COPD. Second, I complete her antibiotic course — 7-10 days for bacteraemic pneumococcal CAP. Third, I arrange vaccination before discharge — pneumococcal conjugate vaccine and influenza vaccine, given at least 2 weeks apart from her acute presentation to ensure immunogenicity. Fourth, I address smoking cessation — this is the single most effective intervention to reduce her future CAP risk — with counselling, varenicline or nicotine replacement therapy, and referral to a cessation program. Fifth, I optimise her COPD and diabetes management — review her inhaler technique, confirm her diabetes medications, and arrange GP follow-up. Sixth, I arrange a repeat chest X-ray at 6 weeks to confirm radiographic resolution — this is essential in a 40 pack-year smoker because a non-resolving pneumonia raises the possibility of an underlying bronchial obstruction, particularly lung cancer. Seventh, I arrange pulmonary rehabilitation and assess her functional recovery.' [1]

Short Case Discussion

Scenario: 'Examine this patient's respiratory system. He was admitted with community-acquired pneumonia.'

Candidate presentation (model): [1]

'I examined Mr Chen's respiratory system. He is comfortable at rest but breathless on mild exertion. He is not cyanosed or clubbed. The respiratory rate is 22 per minute. [1]

The trachea is central. Chest wall expansion is reduced on the right side. On the right lower zone posteriorly, the percussion note is dull. Tactile vocal fremitus is increased over this area. On auscultation, there are bronchial breath sounds, coarse inspiratory and early expiratory crackles, and increased vocal resonance with whispered pectoriloquy over the right lower lobe. There is no wheeze. The left side is unremarkable. [1]

In summary, these findings are consistent with right lower lobe consolidation, in keeping with resolving community-acquired pneumonia.' [1]

Examiner: 'What are bronchial breath sounds and why do they occur in consolidation?' [1]

'Bronchial breath sounds are the tubular breath sounds normally heard only over the trachea and large airways — they have a hollow, tubular quality with an equal inspiratory and expiratory phase and a gap between them. When heard at the periphery, they indicate that consolidated lung tissue is conducting the tracheobronchial sounds outward to the chest wall. Normally, the air-filled alveoli filter out these sounds, producing the soft, low-pitched vesicular breath sounds with their longer inspiratory phase. Consolidation replaces the air with fluid and inflammatory exudate, which conducts sound more effectively than air, allowing the tubular tracheobronchial sounds to reach the periphery. The presence of bronchial breath sounds over an area of dullness, increased vocal resonance, and crackles is the auscultatory hallmark of lobar consolidation.' [1]

Examiner: 'What would change if he had developed a pleural effusion instead?' [1]

'The signs would invert. Instead of increased vocal fremitus, bronchial breathing, and increased vocal resonance, a pleural effusion would produce reduced or absent vocal fremitus, absent or markedly reduced breath sounds, and reduced vocal resonance — because the fluid in the pleural space blocks the transmission of sound from the lung to the chest wall. The percussion note would remain dull or become stony dull. If the effusion is large, the trachea may be deviated away from the effusion, and chest expansion would be reduced on the affected side. The contrast between consolidation (increased transmission, bronchial breathing, increased vocal resonance) and effusion (decreased transmission, absent breath sounds, reduced vocal resonance) — both producing dullness to percussion — is a classic PACES discriminator.' [1]

Examiner: 'His chest X-ray shows a cavity with an air-fluid level. What organisms would you consider?' [1]

'A cavitating lung lesion with an air-fluid level on chest X-ray broadens the differential beyond uncomplicated CAP. The organisms that cause cavitating pneumonia are: Staphylococcus aureus — especially post-influenza and community-acquired MRSA with Panton-Valentine leukocidin, producing necrotising pneumonia with cavitation and pneumatocoeles; Klebsiella pneumoniae — classically in alcoholics and diabetics, with a bulging fissure and thick currant-jelly sputum; anaerobes — from aspiration, producing lung abscess with foul-smelling sputum; Mycobacterium tuberculosis — especially upper lobe predominant; and fungi such as Aspergillus in immunocompromised patients. I would take a careful history for aspiration risk, recent influenza, alcohol use, and immunosuppression, send sputum for Gram stain, culture, and acid-fast bacilli, and consider a CT chest to characterise the cavity and guide further investigation. Empiric therapy would need to cover the likely organisms — vancomycin or linezolid for MRSA if post-influenza or rapidly progressive, and anaerobic cover with clindamycin or amoxicillin-clavulanate if aspiration is suspected.' [1]